doi: 10.3389/fphar.2026.1755175 Received 26 November 2025 Revised 21 January 2026 Accepted 20 February 2026 Published 09 March 2026 Volume 17 - 2026 Edited by Roland Bcker, Charit University Medicine Berlin, Germany Reviewed by Mark Lloyd Dapar, Central Mindanao University, Philippines Kishor Jain, Sinhgad Institutes, India Updates Copyright 2026 Kayesh, Kohara and Tsukiyama-Kohara
However, serious complications, such as gallstones and intestinal obstruction, have been reported in a small proportion of GLP-1 users
Under ROSCA and applicable state consumer protection frameworks, subscription cancellation practices must be transparent and disclosed
Compounded drugs are not FDA-approved as a finished product, though their active ingredients may be FDA-approved